HCM
HUTCHMED (China) Limited American Depositary Shares
Pharmaceutical Preparations
Best Pharmaceutical Stocks 2026 →
HUTCHMED (China) (HCM) Stock: Buy, Sell, or Hold?
$14.94
-0.14 (-0.93%)
▼
5d:
+5.21%
30d:
+10.83%
90d:
+22.46%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (32%)
Quality Score
37/100
Position
EXTENDED
30-Day Fair Range
$13.51 – $14.77
Position: EXTENDED
Forward P/E & Valuation
58.2x
STRETCHED
vs 37.8x historical avg
Wall Street Target
$21.14
+40.2% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$13.02 / $15.48
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: HCM shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When HCM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.58
Based on 10.4% avg growth
INTRINSIC VALUE TODAY
$6.57
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HCM is currently trading at $14.94, which is considered extended relative to its 30-day fair value range of $13.51 to $14.77. From a valuation perspective, the stock is trading at a premium (Forward PE: 58.2) compared to its historical average (37.8). At these levels, the market is pricing in 15.4% annual earnings growth.
Technical Outlook: Technically, HCM is in a strong uptrend. Immediate support is located at $13.02, while resistance sits at $15.48.
Market Sentiment: HCM scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.14 (+40.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HCM is in a strong uptrend. Immediate support is located at $13.02, while resistance sits at $15.48.
Market Sentiment: HCM scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.14 (+40.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$13.51 -
$14.77
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
31.9%
Trading Range & Key Levels
30-Day Trading Range
$13.51 -
$14.77
Current vs Trading Range
EXTENDED
Support Level
$13.02
Resistance Level
$15.48
Current Trend
Strong Uptrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (8/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 40.2% below Wall St target ($21.14)
- BULLISH: Expecting earnings turnaround to 15.4% growth with 0.2% revenue growth
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
58.18
Wall Street Target
$21.14
(+40.2%)
Revenue Growth (YoY)
0.2%
Earnings Growth (YoY)
-96.5%
Profit Margin
3.3%
Valuation Premium vs History
+15.4% premium
PE vs Historical
58.2 vs 37.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+15.4%
(market-implied from PE analysis)
1-Year Target
$17.40
(+15%)
2-Year Target
$20.08
(+33%)
3-Year Target
$23.17
(+54%)
3-Yr Target (if PE normalizes)
(PE: 58→38)
PE COMPRESSION
$15.06
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 58.2, Growth: 16.8%)
$24.03
(+59%)
Base:
(SPY PE: 19.9, Growth: 16.8%)
$8.20
(-46%)
Bear:
(PE: 16.9, Growth: 16.8%)
$6.97
(-54%)
Share HCM Analysis
Share this live HCM analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (HCM)
Bullish
1 Retail Mentions
Reddit / WSB Comments
1
Bullish
Last Tracked
Jan 18, 2026
Daily AI digest
AI Retail Discussion Summary:
Reddit & WallStreetBets discussions on HCM are bullish (sentiment score +0.55) across 1 tracked comments.
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 1:43 PM ET
Data refreshes hourly during market hours. Next update: 2:43 PM
Data refreshes hourly during market hours. Next update: 2:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HCM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$208 | 23 SELL |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$58 | 41 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
15 analysts |
$49 | 36 SELL |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$63 | 51 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive HCM Research Pages
